{'fraction_non_alphanumeric': 0.02912621359223301, 'fraction_numerical': 0.019417475728155338, 'mean_word_length': 5.496062992125984, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Phenylbutazone toxicosis in equidae: a biochemical and pathophysiological study.

Toxic effects of phenylbutazone (PBZ) in ponies and horses were studied, using a variety of biochemical, pathophysiologic, and pathologic methods. At dosage levels of 10 to 12 mg/kg of body weight/day for 8 to 10 days, ponies frequently developed clinical signs of toxicosis characterized by hypoproteinemia. Studies using 51CrCl3 demonstrated that PBZ caused a protein-losing gastroenteropathy. The plasma loss was usually associated with gastrointestinal ulceration, but sometimes occurred without obvious lesions in mildly affected animals. Similar studies (8.2 mg/kg/day for 13 days) in Thoroughbreds indicated that they were less susceptible to PBZ toxicity; however, a degree of hypoproteinemia occurred in 4 of 6 treated Thoroughbreds.